Home | Sitemap    繁體 | English | 简体
About UsInvestor RelationsContact Us

Board of Directors

The Board comprises (i) six executive Directors, namely Mr. Lu Zhiqiang, Mr. Chui Kwong Kau, Mr. Zhang James Jian Yuan, Dr. Sun Yu, Mrs. Cheung Fan Karen and Mr. Lau Ngai Cheung; and (ii) three independent non-executive Directors, namely Mr. Hung Yat Ming, Mr. Chan Yun Hing and Mr. Tang Hua.

Chief Executive Officer and Executive Director

Mr. Lu Zhiqiang (“Mr. Lu”) was appointed as an executive Director and the chief executive officer of the Company on 30 September 2011. Mr. Lu is also the compliance officer, the authorised representative and the directors of various subsidiaries of the Company. He holds a Master of Business Administration Degree from Central State University of the United States of America, a Bachelor Degree in Engineering and a Bachelor Degree in Industry from Nanchang Hangkong University. Mr. Lu attended the programme of a Master of Science Degree from the International Purchasing & Supply Chain Management Audencia NANTES.Ecole de Management. Mr. Lu has many years’ experience in corporate management and investment. Mr. Lu is currently an executive director of Extrawell Pharmaceutical Holdings Limited (stock code: 858). He was an executive director of Global Energy Resources International Group Limited (Stock code: 8192) from 28 November 2014 to 2 September 2016 and a non-executive director of Lamtex Holdings Ltd (formerly known as China New Energy Power Group Limited) (stock code: 1041) from 29 October 2014 to 9 July 2015.

Executive Directors

Mr. Chui Kwong Kau (“Mr. Chui”) was appointed as a non-executive Director on 19 October 2009 and subsequently re-designated as an executive Director on 30 November 2009. Mr. Chui is also a member of the remuneration committee, the authorized representative, the agent for the service of process in Hong Kong and the directors of various subsidiaries of the Company. He has over 20 years’ experience in financial management, accounting and auditing fields. Mr. Chui is currently a non-executive director of each of Hsin Chong Group Holdings Limited (stock code: 404), Boill Healthcare Holdings Limited (formerly known as Ngai Shun Holdings Limited) (stock code: 1246) and DeTai New Energy Group Limited (stock code: 559). He was an executive director of China Energy Development Holdings Limited (stock code: 228) from 5 October 2005 to 30 June 2016 and an independent non-executive director of Aurum Pacific (China) Group Limited (stock code: 8148) from 17 March 2010 to 16 March 2016.

Mr. Zhang James Jian Yuan (“Mr. Zhang”) has been re-designated from an independent non-executive Director to an executive Director on 26 September 2018. Mr. Zhang was appointed as an independent non-executive Director on 7 July 2017. Mr. Zhang has over 25 years of experience in financial and banking industry, including positions in private wealth management at Merrill Lynch and as a managing director of investment banking at TerraNova Capital Partners, Inc. Mr. Zhang is currently a director of BioLight Life Sciences Ltd since May 2015, the shares of which are listed on Tel-Aviv Stock Exchange (Stock Code: BOLT). Mr. Zhang is a business partner with a substantial shareholder of the Company in certain private companies. Mr. Zhang is a minority shareholder and a director of these private companies. Mr. Zhang holds a Master of Arts from Brooklyn College of the City University of New York and a Bachelor of Arts in Accounting from Jinan University in Guangzhou, China.

Mrs. Cheung Fan Karen (“Mrs. Cheung”) has been appointed as an executive Director with effect from 26 September 2018. Mrs. Cheung has many years of experience in management and investment including construction works and medical equipment. Mrs. Cheung is a director of Rock-One Engineering Company Limited and Rock-One Group Life Sciences Investment Limited. Mrs. Cheung is the spouse of Mr. Lau Ngai Cheung (“Mr. Lau”), a substantial shareholders of the Company, and is also a business partner with Mr. Zhang James Jian Yuan, an executive Director. Mrs. Cheung holds a Master of Business Administration from Peking University and Bachelor degree in civil engineering from Huaqiao University. 

Mr. Lau Ngai Cheung (“Mr. Lau”) has been appointed as an executive Director with effect from 25 January 2019. Mr. Lau has many years of experience in management and investment including construction and reclamation works and medical equipment. Mr. Lau is a director and a major shareholder of Rock-One Engineering Company Limited and Rock-One Group Life Sciences Investment Limited. Mr. Lau is the spouse of Mrs. Cheung Fan Karen (“Mrs. Cheung”), an executive Director, and a substantial shareholder of the Company. Mr. Lau also a business partner with Mr. Zhang James Jian Yuan, an executive Director. Mr. Lau holds a bachelor’s degree in engineering from Wahnan Industrial College, the People's Republic of China (now known as South China University of Technology).

Independent Non-executive Directors

Mr. Hung Yat Ming (“Mr. Hung”) was appointed as an independent non-executive Director on 28 March 2013. Mr. Hung is also the chairman of each of the audit committee, the remuneration committee and the nomination committee of the Company. He graduated from The University of Hong Kong with a Bachelor degree in Mathematics and obtained a graduate diploma in Accounting from University of Strathclyde, Glasgow. Mr. Hung has over 30 years of experience in accounting and finance and is a financial controller of a Hong Kong listed company. He is a member of The Institute of Chartered Accountants of Scotland and Hong Kong Institute of Certified Public Accountants. Mr. Hung is currently an independent nonexecutive director of each of Asia Standard Hotel Group Limited (stock code: 292) and Asia Orient Holdings Limited (stock code: 214). He was an independent non-executive director of Sunway International Holdings Limited (stock code: 58) from 28 February 2013 to 20 May 2015.

Mr. Chan Yun Hing (“Mr. Chan”) was appointed as an independent non-executive Director on 21 September 2012. Mr. Chan is also the member of each of the audit committee, the remuneration committee and the nomination committee of the Company. He holds a degree of Master of Business Administration from Research Institute of Tsinghua University in Shenzhen (RITS), China — University of Wales. Mr. Chan is currently the director and consultant of Huizhou Da Ya Wan Hui Li Group Limited*. He is also the Standing Committee Member of Guangdong Huizhow of the Chinese People’s Political Consultative Conference, the Vice Chairman and the Secretary- General of Hong Kong Federation of Huichow Associations Limited and the Deputy Secretary-General of Hong Kong Federation of Guangdong Hakka Associations.

Mr. Tang Hua (“Mr. Tang”) has been appointed as an independent non-executive Director and member of each of audit committee, remuneration committee and nomination committee of the Company with effect from 26 September 2018. Mr. Tang has over 26 years of experience in pharmaceutical and medical devices industry including operations management, sales and marketing, product development and registration. Mr. Tang served as general manager of Shaanxi Aierfu Activtissue Engineering Company Limited and Shenzhen AiNear Cornea Engineering Company Limited from 2008 to 2015 and executive director of 廣東康嘉投資有限公司 廣東康嘉投資有限公司 (Guangdong Kang Jia Investment Company Limited*) from 2015 to 2017. He is an executive director of 西安盤古醫藥科技 西安盤古醫藥科技 有限公司 (Xian Pan Gu Medicine Technology Company Limited*) since 2017. Mr. Tang graduated from Shaanxi College of Traditional Chinese Medicine (now known as Shaanxi University of Chinese Medicine) in Traditional Chinese Medicine. Mr. Tang is a licensed pharmacist of Chinese Medicine issued by the State Administration of Traditional Chinese Medicine of the People's Republic of China.